ENOVIS CORP (ENOV) Stock Fundamental Analysis
NYSE:ENOV - New York Stock Exchange, Inc. - US1940141062 - Common Stock - Currency: USD
Taking everything into account, ENOV scores 4 out of 10 in our fundamental rating. ENOV was compared to 187 industry peers in the Health Care Equipment & Supplies industry. ENOV may be in some trouble as it scores bad on both profitability and health. ENOV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year ENOV was profitable.
In the past year ENOV had a positive cash flow from operations.
In multiple years ENOV reported negative net income over the last 5 years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV's Return On Assets of -16.60% is in line compared to the rest of the industry. ENOV outperforms 52.41% of its industry peers.
Looking at the Return On Equity, with a value of -30.92%, ENOV is in line with its industry, outperforming 55.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.6% | ||
| ROE | -30.92% | ||
| ROIC | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ENOV has declined.
With a Gross Margin value of 55.68%, ENOV perfoms like the industry average, outperforming 52.41% of the companies in the same industry.
In the last couple of years the Gross Margin of ENOV has grown nicely.
ENOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.68% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENOV has more shares outstanding than it did 1 year ago.
ENOV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ENOV has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.00, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
ENOV's Altman-Z score of 1.00 is in line compared to the rest of the industry. ENOV outperforms 49.73% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that ENOV is somewhat dependend on debt financing.
ENOV has a worse Debt to Equity ratio (0.52) than 61.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1 |
ROIC/WACCN/A
WACC8.29%
2.3 Liquidity
A Current Ratio of 2.55 indicates that ENOV has no problem at all paying its short term obligations.
With a Current ratio value of 2.55, ENOV perfoms like the industry average, outperforming 48.66% of the companies in the same industry.
A Quick Ratio of 1.32 indicates that ENOV should not have too much problems paying its short term obligations.
The Quick ratio of ENOV (1.32) is worse than 66.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.55 | ||
| Quick Ratio | 1.32 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 27.64% over the past year.
The earnings per share for ENOV have been decreasing by -16.18% on average. This is quite bad
ENOV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.32%.
ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.73% yearly.
EPS 1Y (TTM)27.64%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%62%
Revenue 1Y (TTM)18.32%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.25%
3.2 Future
Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.19% on average per year.
The Revenue is expected to grow by 8.87% on average over the next years. This is quite good.
EPS Next Y9.12%
EPS Next 2Y11.06%
EPS Next 3Y12.89%
EPS Next 5Y23.19%
Revenue Next Year6.39%
Revenue Next 2Y6.29%
Revenue Next 3Y6.46%
Revenue Next 5Y8.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.99, which indicates a very decent valuation of ENOV.
Based on the Price/Earnings ratio, ENOV is valued cheaply inside the industry as 94.65% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.15, ENOV is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.98, the valuation of ENOV can be described as very reasonable.
Based on the Price/Forward Earnings ratio, ENOV is valued cheaper than 94.12% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.60, ENOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.99 | ||
| Fwd PE | 8.98 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 86.63% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 12 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ENOV's earnings are expected to grow with 12.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.09
PEG (5Y)N/A
EPS Next 2Y11.06%
EPS Next 3Y12.89%
5. Dividend
5.1 Amount
ENOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.36
-0.42 (-1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners117.87%
Inst Owner Change10.23%
Ins Owners1.15%
Ins Owner Change15.2%
Market Cap1.79B
Analysts83.53
Price Target59.84 (90.82%)
Short Float %11.53%
Short Ratio5.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.89%
Min EPS beat(2)4.97%
Max EPS beat(2)6.8%
EPS beat(4)4
Avg EPS beat(4)7.65%
Min EPS beat(4)2.6%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)6.64%
EPS beat(12)12
Avg EPS beat(12)9.41%
EPS beat(16)15
Avg EPS beat(16)7.5%
Revenue beat(2)0
Avg Revenue beat(2)-1.45%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.93%
Revenue beat(4)0
Avg Revenue beat(4)-1.69%
Min Revenue beat(4)-2.12%
Max Revenue beat(4)-0.93%
Revenue beat(8)3
Avg Revenue beat(8)-0.94%
Revenue beat(12)4
Avg Revenue beat(12)-1.16%
Revenue beat(16)5
Avg Revenue beat(16)-12.52%
PT rev (1m)-9.92%
PT rev (3m)-10.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.66%
EPS NY rev (1m)-1.1%
EPS NY rev (3m)-4.91%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)1.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.99 | ||
| Fwd PE | 8.98 | ||
| P/S | 0.83 | ||
| P/FCF | N/A | ||
| P/OCF | 12.1 | ||
| P/B | 0.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12 |
EPS(TTM)3.14
EY10.01%
EPS(NY)3.49
Fwd EY11.13%
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)2.59
OCFY8.27%
SpS37.64
BVpS45.83
TBVpS-8.06
PEG (NY)1.09
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.6% | ||
| ROE | -30.92% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.68% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score4
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.18 | ||
| Cap/Depr | 66.14% | ||
| Cap/Sales | 8.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 56.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.55 | ||
| Quick Ratio | 1.32 | ||
| Altman-Z | 1 |
F-Score4
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.64%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%62%
EPS Next Y9.12%
EPS Next 2Y11.06%
EPS Next 3Y12.89%
EPS Next 5Y23.19%
Revenue 1Y (TTM)18.32%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%8.25%
Revenue Next Year6.39%
Revenue Next 2Y6.29%
Revenue Next 3Y6.46%
Revenue Next 5Y8.87%
EBIT growth 1Y-171.96%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year71.76%
EBIT Next 3Y30.46%
EBIT Next 5Y28.11%
FCF growth 1Y73.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y535.73%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%